Emergent BioSolutions receives EMA prime designation for its chikungunya virus VLP vaccine
Emergent BioSolutions announced the company’s chikungunya virus virus-like particle vaccine candidate, CHIKV VLP, was granted PRIority MEdicines, or PRIME, designation by the CHMP of the EMA during its September meeting. The CHIKV VLP vaccine candidate is licensed from the NIH. October 10, 2019